Ortataxel
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
ECHA InfoCard | 100.158.836 |
Chemical and physical data | |
Formula | C44H57NO17 |
Molar mass | 871.930 g·mol−1 |
3D model (JSmol) | |
Ortataxel is a drug used in chemotherapy. As of June 2009, Spectrum Pharmaceuticals has the drug in a Phase 2 clinical trial.[1]
References[]
- ^ Silvani A, De Simone I, Fregoni V, Biagioli E, Marchioni E, Caroli M, Salmaggi A, Pace A, Torri V, Gaviani P, Quaquarini E, Simonetti G, Rulli E, D'Incalci M (May 2019). "Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma". Journal of Neuro-oncology. 142 (3): 455–462. doi:10.1007/s11060-019-03116-z. PMID 30726533.
Categories:
- Drugs not assigned an ATC code
- Mitotic inhibitors
- Benzoate esters
- Carbamates
- Secondary alcohols
- Lactones
- Acetate esters
- Taxanes
- Antineoplastic and immunomodulating drug stubs